In addition, the results of our in vivo experiments on the promoting roles of FAP overexpression and IL-17a upregulation should be further validated in genetically engineered mice with high IL-17a or FAP expression in HSCs using a chemically induced liver cancer model to make the results more convincing. This evidence concerns the gene IL17A and liver cancer.